NPPA demand notice of ~₹ 4.88 crore over alleged DPCO 2013 pricing violation
Corona Remedies has received a Demand Notice from the National Pharmaceutical Pricing Authority (NPPA).
By ScoutQuest · · 2 min read
- Total demand amount
- ~₹ 4.88 crore, which includes interest and penalty
- Alleged violation
- Para 15 of the Drugs (Prices Control) Order, 2013 — prior price approval
- Notice received date
- November 03, 2026
Regulatory demand notice received
Corona Remedies has disclosed that it has received a Demand Notice from the National Pharmaceutical Pricing Authority (NPPA), which sits under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The notice was received on November 03, 2026, the same date as the exchange intimation.
The amount involved
- The total demand is ~₹ 4.88 crore.
- This amount is stated to include interest and penalty.
- The demand relates to an alleged violation of Para 15 of the Drugs (Prices Control) Order, 2013 (DPCO 2013).
What the alleged issue is about
The update describes the matter as an issue regarding prior price approval under DPCO 2013. DPCO is the framework under which the government controls prices of scheduled medicines, and it sets out how a company must get its prices approved before selling.
What the company says
- The company is currently evaluating the demand notice.
- It will take further steps in its interests in accordance with applicable laws.
- On impact, the company states that the Demand Notice does not have any material financial impact on it.
How to read this
A demand notice is a claim by the regulator, and the company's own wording is that the violation is "alleged". The company has said it is still evaluating the notice and has described the financial impact as not material. The notice has been received; the company has not said it has paid the amount.
What to watch
- Any update from the company on how it responds to the notice, such as a reply, a challenge or a settlement.
- Any change in the company's stated assessment of the financial impact.
In short: a sub-crore-scale, single-figure regulatory demand on a pricing-approval issue, which the company has told investors it does not expect to affect its finances materially.
Also from Corona Remedies
Corona Remedies makes Q2H1FY27 earnings conference call audio recording available on website
2 Nov 2026
Corona Remedies officials to hold 1x1/group investor meetings in London on Nov 4 and UAE on Nov 5-6, 2026
31 Oct 2026
Corona Remedies Q2 FY27 revenue up 22.2% to INR 441.2 Cr; H1 PAT up 22.2% to INR 120.4 Cr
30 Oct 2026
More numbers
- Total NPPA demand including interest and penalty₹ 4,87,97,160/-
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.